NEW YORK (360Dx) – Angle this week announced its preliminary financial results for the fiscal year ended April 30. The liquid biopsy company reported revenues increased to £700,000 ($917,847) from £500,000 in 2017. The firm's loss for the year widened to £7.5 million from £6.4 million, reflecting planned investment to develop and validate clinical application and commercial use of the Parsortix system.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.